FDA Antimicrobial Drugs Advisory Committee recommends approval of pretomanid

FDA Antimicrobial Drugs Advisory Committee recommends approval of pretomanid

Posted on 6/21/19

Investigational drug pretomanid is under regulatory review by FDA for treatment of XDR-TB and treatment-intolerant or non-responsive MDR-TB as part of a new investigational regimen. A decision regarding pretomanid approval is expected to be made by August of 2019.

For more news, click here.